Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 12, 2016 - Issue 1
Submit an article Journal homepage
568
Views
31
CrossRef citations to date
0
Altmetric
Reviews

miRNAs in melanoma: a defined role in tumor progression and metastasis

Francesco MannavolaDIMO, Department of Internal Medicine and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, Italy
,
Marco TucciDIMO, Department of Internal Medicine and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, ItalyCorrespondence[email protected]
,
Claudia FeliciDIMO, Department of Internal Medicine and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, Italy
,
Stefania StucciDIMO, Department of Internal Medicine and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, Italy
&
Franco SilvestrisDIMO, Department of Internal Medicine and Clinical Oncology, University of Bari ‘Aldo Moro’, Bari, Italy
Pages 79-89 | Published online: 27 Oct 2015

References

  • Reference annotations
  • * Of interest
  • ** Of considerable interest
  • Tucci M, Stucci S, Passarelli A, et al. The immune escape in the melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol. 2014;10:1395–1404.
  • Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. Biomed Res Int. 2015;2015:851387.
  • Howell PM Jr, Liu S, Ren S, et al. Epigenetics in human melanoma. Cancer Control. 2009;16:200–218.
  • Luo C, Weber CE, Osen W, et al. The role of microRNAs in melanoma. Eur J Cell Biol. 2014;93:11–22.
  • Lee Y, Jeon K, Lee JT, et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002;21:4663–4670.
  • Kwon SM, Cho H, Choi JH, et al. Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform. 2012;10:69–73.
  • Kohlhapp FJ, Mitra AK, Lengyel E, et al. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015. DOI:10.1038/onc.2015.89.
  • Segura MF, Greenwald HS, Hanniford D, et al. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis. 2012;33:1823–1832.
  • Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol. 2006;33:167–173.
  • Iorio MV, Croce CM. MicroRNA involvement in human cancer. Carcinogenesis. 2012;33:1126–1133.

It describes the capability of miRNAs to act as oncogenes and oncosuppressors driving tumorigenesis

  • Bao B, Ali S, Ahmad A, et al. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev. 2014;23:1947–1958.
  • Ahmad A, Sethi S, Chen W, et al. Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res. 2014;6:384–390.
  • Mueller DW, Rehli M, Bosserhoff AK. MiRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Inv Dermatol. 2009;129:1740–1751.
  • Sand M. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351:85–98.
  • Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70:4163–4173.

It is an overview that describes the major miRNAs implicated in melanomagenesis

  • Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 2004;17:318–325.
  • Lekmine F, Chang CK, Sethakorn N, et al. Role of microphthalmia transcription factor (MITF) in melanoma differentiation. Biochem Biophys Res Commun. 2007;354:830–835.
  • Bemis LT, Chen R, Amato CM, et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008;68:1362–1368.
  • Guo J, Zhang JF, Wang WM, et al. MicroRNA-218 inhibits melanogenesis by directly suppressing microphthalmia-associated transcription factorexpression. RNA Biol. 2014;11:732–741.
  • Couts KL, Anderson EM, Gross MM, et al. Oncogenic B-RAF signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene. 2013;32:1959–1970.
  • Forloni M, Dogra SK, Dong Y, et al. MiR-146a promotes the initiation and progression of melanoma by activating Notch signalling. eLife. 2014. DOI:10.7554/eLife.01460.
  • Poenitzsch Strong AM, Setaluri V, Spiegelman VS. MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys. 2014;563:118–124.
  • Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep. 2012;14:449–457.
  • Karreth FA, Tay Y, Perna D, et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–395.
  • Dar AA, Majid S, de Semir D, et al. MiRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem. 2011;286:16606–16614.
  • Noguchi S, Mori T, Otsuka Y, et al. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem. 2012;287:11769–11777.
  • Felicetti F, Errico MC, Segnalini P, et al. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther. 2008;8:1759–1765.
  • Asangani IA, Harms PW, Dodson L, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012;3:1011–1025.
  • Lindor NM, Jalal SM, Kumar S, et al. Multiple primary tumors associated with chromosome 9p deletion. Am J Med Genet A. 2007;143A:95–97.
  • Poliseno L, Haimovic A, Segura MF, et al. Histology-specific microRNA alteration in melanoma. J Invest Dermatol. 2012;132:1860–1868.
  • Chan E, Patel R, Nallur S, et al. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011;10:1845–1852.
  • Babapoor S, Fleming E, Wu R, et al. A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion. PLoS One. 2014. DOI:10.1371/journal.pone.0107502.
  • Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–354.
  • Brandner JM, Haass NK. Melanoma’s connections to the tumour microenvironment. Pathology. 2013;45:443–452.
  • Suzuki HI, Katsura A, Matsuyama H, et al. MicroRNA regulons in tumor microenvironment. Oncogene. 2014. DOI:10.1038/onc.2014.254.

It elucidates the major mechanisms activated in tumor microenvironment by miRNAs.

  • Gaziel-Sovran A, Segura MF, Di Micco R, et al. miR30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011;20:104–118.
  • Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997;71:630–637.
  • Liu S, Kumar SM, Lu H, et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kB1-Snail1 pathway in melanoma. J Pathol. 2012;226:61–72.
  • Kawanishi K, Doki Y, Shiozaki H, et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am J Clin Pathol. 2000;113:266–274.
  • Fenger JM, Bear MD, Volinia S, et al. Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis. BMC Cancer. 2014;14:84.
  • Zhang H, Qi M, Li S, et al. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther. 2012;11:1454–1466.
  • Zheng L, Qi T, Yang D, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting Cyclin D1 and Ets1. PLoS One. 2013;8:e55719.
  • Zhuang G, Wu X, Jiang Z, et al. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31:351323.
  • Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068–1082.
  • Akers JC, Gonda D, Kim R, et al. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113:1–11.
  • Gajos-Michniewicz A, Duechler M, Czyz M. MiRNA in melanoma-derived exosomes. Cancer Letters. 2014;347:29–37.
  • Roma-Rodrigues C, Fernandes AR, Baptista PV. Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells. Biomed Res Int. 2014;2014:179486.
  • Valenti R, Huber V, Iero M, et al. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007;67:2912–2915.
  • Ye SB, Li ZL, Luo DH, et al. Tumor derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014;5:5439–5452.
  • Wang T, Gilkes DM, Takano N, et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that timulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA. 2014;111:E3234–E3242.
  • Wang X, Ding X, Nan L, et al. Investigation of the roles of exosomes in colorectal cancer liver metastasis. Oncol Rep. 2015;33:2445–2453.
  • Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011;71:3792–3801.
  • Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nat Rev Immunol. 2007;7:4151.
  • O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111–122.
  • Pyfferoen L, Mestdagh P, Vergote K, et al. Lung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level. Int J Cancer. 2014;135:2868–2877.
  • Du J, Wang J, Tan G, et al. Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activation. Med Oncol. 2012;29:2814–2823.
  • Riepsaame J, van Oudenaren A, den Broeder BJ, et al. MicroRNA-mediated down-regulation of M-CSF receptor contributes to maturation of mouse monocyte-derived dendritic cells. Front in Immunol. 2013;4:353.
  • Tuner ML, Schnorfeil FM, Brocker T. MicroRNAs regulate dendritic cell differentiation and function. J Immunol. 2011;187:3911–3917.
  • Lu C, Huang X, Zhang X, et al. MiR-221 and miR-155 regulate human dendritic cell developement, apopotosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117:4293–4303.
  • Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–611.
  • Bai Y, Qian C, Qian L, et al. Integrin CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating microRNA-146a. J Immunol. 2012;188:5293–5302.
  • Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA. 2009;106:2735–2740.
  • Alexander M, Hu R, Runtsch MC, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;18(6):7321.
  • Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–631.
  • Gabrilovich DI, Nagaraj S. Myeloid-derived-suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174.
  • Liu Q, Zhang M, Jiang X, et al. MiR-223 suppresses differentiation of tumor-induced CD11b+ Gr1+ myeloid-derived suppressor cells from bone marrow cells. Int J Cancer. 2011;129:2662–2673.
  • Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol. 2012;188:5500–5510.
  • Li L, Zhang J, Diao W, et al. MicroRNA-155 and microRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol. 2014;192:1034–1043.
  • Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010;21:49–59.
  • Zhang M, Liu Q, Mi S, et al. Both miR-175p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol. 2011;186:4716–4724.
  • Shevach EM. Mechanisms of foxp3 T regulatory cell-mediated suppression. Immunity. 2009;30:636–645.
  • Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007;445:931–935.
  • Zheng Y, Josefowicz SZ, Kas A, et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445:936–940.
  • Stahl HF, Fauti T, Ullrich N, et al. MiR-155 inhibition sensitizes CD4+ Th cells for Treg mediated suppression. PLoS One. 2009. DOI:10.1371/journal.pone.0007158.
  • Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142:914–929.
  • Lykken E, Feng F, Sevilla J, et al. Molecular dissection of the miR-17-92 cluster’s critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood. 2011;118:5487–5497.
  • Fayyad-Kazan H, Rouas R, Fayyad-Kazan M, et al. MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem. 2012;287:9910–9922.
  • Apostolou I, Verginis P, Kretschmer K, et al. Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol. 2008;28:619–624.
  • Zhou Q, Haupt S, Prots I, et al. miR-142-3p is involved in CD25+ CD4 T cell proliferation by targeting the expression of glycoprotein A repetitions predominant. J Immunol. 2013;190:6579–6588.
  • Gauthy E, Cuende J, Stockis J, et al. GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells. PLoS One. 2013. DOI:10.1371/journal.pone.0076186.
  • Jebbawi F, Fayyad-Kazan H, Merimi M, et al. A microRNA profile of human CD8. J Trans Med. 2014;12:218.
  • Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252.
  • Sceneay J, Smyth MJ, Möller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013;32:449–464.
  • Deng J, Liu Y, Lee H, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012;21:642–654.
  • Penna E, Orso F, Cimino D, et al. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011;30:1990–2007.
  • Worley LA, Long MD, Onken MD, et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18:184–190.
  • Lee YB, Bantounas I, Lee DY, et al. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res. 2009;37:123–128.
  • Juan AH, Kumar RM, Marx JG, et al. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell. 2009;36:61–74.
  • Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem. 2007;14:377–386.
  • Longo N, Yáñez-Mó M, Mittelbrunn M, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood. 2001;98:3717–3726.
  • Liang S, Sharma A, Peng HH, et al. Targeting mutant (V600E) B-RAF in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res. 2007;67:5814–5820.
  • Hilger-Eversheim K, Moser M, Schorle H, et al. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene. 2000;260:1–12.
  • Eckert D, Buhl S, Weber S, et al. The AP-2 family of transcription factors. Genome Biol. 2005;6:246.
  • Gershenwald JE, Sumner W, Calderone T, et al. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001;20:3363–3375.
  • Huang S, Jean D, Luca M, et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 1998;17:4358–4369.
  • Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 2008;7:997–1003.
  • Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22:894–907.
  • Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62:1315–1326.
  • Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. Plos One. 2010. DOI:10.1371/journal.pone.0013176.
  • Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA. 2009;106:1814–1819.
  • Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2011;30:1481–1488.
  • Loercher AE, Tank EM, Delston RB, et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol. 2005;168:35–40.
  • Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005;433:764–769.
  • Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006;2:3426–3439.
  • Kim J, Choi H, Cho EG, et al. FoxO3a is an antimelanogenic factor that mediates antioxidant-induced depigmentation. J Invest Dermatol. 2014;134:1378–1388.
  • Shiota M, Song Y, Yokomizo A, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res. 2010;16:5654–5663.
  • Bu P, Yang P. MicroRNA-203 inhibits malignant melanoma cell migration by targeting versican. Exp Ther Med. 2014;8:309–315.
  • Siragam V, Rutnam ZJ, Yang W, et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget. 2012;3:1370–1385.
  • Li F, Li XJ, Qiao L, et al. MiR-98 suppresses melanoma metastasis trough a negative feedback loop with target gene IL-6. Exp J Med. 2014. DOI:10.1038/emm.2014.63.
  • Schultz J, Lorenz P, Gross G, et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18:549–557.
  • Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–891.
  • Le MT, Hamar P, Guo C, et al. miR-200-conteining extracellular vescicles promote breast cancer cell metastasis. J Clin Invest. 2014;124:5109–5128.
  • Valencia K, Luis-Ravelo D, Bovy N, et al. MiRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol. 2014;8:689–703.

It describes the critical role of exosome-derived miRNA in the regulation of cancer cell osteotropism

  • Shiiyama R, Fukushima S, Jinnin M, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013;23:366–372.
  • Saldanha G, Potter L, Shendge P, et al. Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. J Invest Dermatol. 2013;133:1381–1384.
  • Fleming NH, Zhong J, Pires da Silva I, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015;121:51–59.

This paper focus the potential clinical impact of circulating miRNA measurement and their potential prognostic role in melanoma.

  • Satzger I, Mattern A, Kuettler U, et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer. 2010;126:2553–2562.
  • Ono S, Oyama T, Lam S, et al. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget. 2015;6:9.
  • van Kempen LC, van den Hurk K, Lazar V, et al. Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch. 2012;461:441–448.
  • Segura MF, Belitskaya-Lévy I, Rose AE, et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res. 2010;16:1577–1586.
  • Zhou Y, Zhang L, Fan J, et al. Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells. Melanoma Res. 2015;25:119–126.
  • Peng W, Hu J, Zhu XD, et al. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol. 2014;35:2983–2988.
  • van Zandwijk N, Pavlakis N, Kao S, et al. P1.02MesomiR 1: A Phase I study of TargomiRs in patients with refractory malignant pleural mesothelioma (MPM) and lung cancer (NSCLC). Ann Oncol. 2015;26(Suppl 2):ii16.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.